Involvement of Urokinase-Type Plasminogen Activator System in Cancer: An Overview

Medicinal Research Reviews

Volumn 34, Issue 5, 2014, Pages 918-956

  Mekkawy, Ahmed H ^a   Pourgholami, Mohammad H ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer; Invasion; Metastasis; Prognosis; Urokinase

Indexed keywords

ALPHA 2 ANTIPLASMIN; CANCER GROWTH FACTOR; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; EXTRACELLULAR MATRIX; HUMAN; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MOUTH CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN DEGRADATION; STOMACH CANCER; THYROID CANCER; TUMOR INVASION; URINARY TRACT CANCER; UTERINE CERVIX CANCER; CHEMISTRY; CLASSIFICATION; DISEASE COURSE; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY;

DISEASE PROGRESSION; HUMANS; NEOPLASMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84905495495     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21308     Document Type: Article

References (353)

1. Baldini E, Sorrenti S, D'Armiento E, Di Matteo FM, Catania A, Ulisse S. The urokinase plasminogen activating system in thyroid cancer: Clinical implications. Il Giornale di chirurgia 2012;33(10):305-310.
2. O'Rourke J, Jiang X, Hao Z, Cone RE, Hand AR. Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. J Neurosci Res 2005;79(6):727-733.
3. Hoyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007;44:65-102.
4. Schmitt M, Harbeck N, Brunner N, Janicke F, Meisner C, Muhlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011;11(6):617-634.
5. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987;262(10):4437-4440.
6. Petersen LC, Lund LR, Nielsen LS, Dano K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988;263(23):11189-11195.
7. Schmitt M, Goretzki L, Janicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 1991;50(4-6):731-741.
8. Fowler B, Mackman N, Parmer RJ, Miles LA. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR. Thromb Haemost 1998;80(1):148-154.
9. Rabbani SA, Rajwans N, Achbarou A, Murthy KK, Goltzman D. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. FEBS Lett 1994;338(1):69-74.
10. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991;266(3):1926-1933.
11. Montuori N, Rossi G, Ragno P. Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells. FEBS Lett 1999;460(1):32-36.
12. Andolfo A, English WR, Resnati M, Murphy G, Blasi F, Sidenius N. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost 2002;88(2):298-306.
13. Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol 2004;172(1):540-549.
14. Beaufort N, Leduc D, Rousselle JC, Namane A, Chignard M, Pidard D. Plasmin cleaves the juxtamembrane domain and releases truncated species of the urokinase receptor (CD87) from human bronchial epithelial cells. FEBS Lett 2004;574(1-3):89-94.
15. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: Degradation products or active molecules? Thromb Haemost 2005;93(2):192-198.
16. Zhou HM, Nichols A, Meda P, Vassalli JD. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 2000;19(17):4817-4826.
17. Ronne E, Pappot H, Grondahl-Hansen J, Hoyer-Hansen G, Plesner T, Hansen NE, Dano K. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995;89(3):576-581.
18. Lomholt AF, Hoyer-Hansen G, Nielsen HJ, Christensen IJ. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer 2009;101(6):992-997.
19. Riisbro R, Stephens RW, Brunner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhoff GF. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 2001;82(3):523-531.
20. Ellis V. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. J Biol Chem 1996;271(25):14779-14784.
21. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991;266(19):12752-12758.
22. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989;264(4):2185-2188.
23. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002;99(3):1359-1364.
24. Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, Menez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005;24(9):1655-1663.
25. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1995;181(4):1381-1390.
26. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996;273(5281):1551-1555.
27. Xue W, Mizukami I, Todd RF, 3rd, Petty HR. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res 1997;57(9):1682-1689.
28. De Bock CE, Lin Z, Mekkawy AH, Byrne JA, Wang Y. Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. Int J Oncol 2010;36(5):1155-1163.
29. Mekkawy AH, De Bock CE, Lin Z, Morris DL, Wang Y, Pourgholami MH. Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun 2010;399(4):738-743.
30. Mekkawy AH, Morris DL, Pourgholami MH. HAX1 augments cell proliferation, migration, adhesion, and invasion induced by urokinase-type plasminogen activator receptor. J Oncol 2012;2012:950749.
31. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994;54(11):3066-3071.
32. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996;15(7):1572-1582.
33. Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 1997;172(2):137-145.
34. Xu X, Gardsvoll H, Yuan C, Lin L, Ploug M, Huang M. Crystal structure of the urokinase receptor in a ligand-free form. J Mol Biol 2012;416(5):629-641.
35. Ploug M, Ostergaard S, Hansen LB, Holm A, Dano K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 1998;37(11):3612-3622.
36. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction. FEBS Lett 1997;420(1):79-85.
37. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 1998;188(6):1029-1037.
38. Gardsvoll H, Kjaergaard M, Jacobsen B, Kriegbaum MC, Huang M, Ploug M. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. J Biol Chem 2011;286(50):43515-43526.
39. Collen D. Ham-Wasserman lecture: Role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 2001;2001(1):1-9.
40. Kornberg A, Francis CW, Marder VJ. Plasma crosslinked fibrin polymers: Quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders. Blood 1992;80(3):709-717.
41. Mekkawy AH, Morris DL, Pourgholami MH. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol 2009;5(9):1487-1499.
42. Fukao H, Ueshima S, Okada K, Matsuo O. The role of the pericellular fibrinolytic system in angiogenesis. Jpn J Physiol 1997;47(2):161-171.
43. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor-1 and tissue plasminogen-activator. Biochem J 1990;265(1):109-113.
44. Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 1988;175(1):33-39.
45. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmuller S, Kiechle M, Janicke F, Thomssen C, Chemo NSG. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013;49(8):1825-1835.
46. Halamkova J, Kiss I, Pavlovsky Z, Jarkovsky J, Tomasek J, Tucek S, Hanakova L, Moulis M, Cech Z, Zavrelova J, Penka M. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Hepatogastroenterology 2011;58(112):1918-1925.
47. Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N, Klijn JG, Foekens JA. Urokinase-type plasminogen activator system in breast cancer: Association with tamoxifen therapy in recurrent disease. Cancer Res 2004;64(13):4563-4568.
48. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart JM. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002;16(2):147-154.
49. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996;383(6599):441-443.
50. Mikus P, Urano T, Liljestrom P, Ny T. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur J Biochem 1993;218(3):1071-1082.
51. Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 2002;106(18):2372-2378.
52. Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, Muschel RJ. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004;64(23):8613-8619.
53. Langer F, Amirkhosravi A, Ingersoll SB, Walker JM, Spath B, Eifrig B, Bokemeyer C, Francis JL. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2006;4(5):1056-1062.
54. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269(51):32380-32388.
55. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996;224(2):344-353.
56. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134(6):1563-1571.
57. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 1996;271(22):12716-12723.
58. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997;232(2):420-429.
59. Degryse B, Sier CF, Resnati M, Conese M, Blasi F. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett 2001;505(2):249-254.
60. Menoud PA, Sappino N, Boudal-Khoshbeen M, Vassalli JD, Sappino AP. The kidney is a major site of alpha(2)-antiplasmin production. J Clin Invest 1996;97(11):2478-2484.
61. Sumi Y, Ichikawa Y, Nakamura Y, Miura O, Aoki N. Expression and characterization of pro alpha 2-plasmin inhibitor. J Biochem 1989;106(4):703-707.
62. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78(12):3114-3124.
63. del Zoppo GJ. Plasminogen activators in ischemic stroke: Introduction. Stroke 2010;41(Suppl 10):S39-S41.
64. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001;936:226-236.
65. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17(5):548-558.
66. Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFbeta in cancer. FEBS Lett 2012;586(14):1959-1970.
67. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2(6):689-692.
68. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007;178(3):425-436.
69. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem 2009;284(34):22825-22833.
70. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998;273(14):8502-8507.
71. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147(1):89-104.
72. Monaghan-Benson E, McKeown-Longo PJ. Urokinase-type plasminogen activator receptor regulates a novel pathway of fibronectin matrix assembly requiring Src-dependent transactivation of epidermal growth factor receptor. J Biol Chem 2006;281(14):9450-9459.
73. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1(5):445-457.
74. Jo M, Thomas KS, Takimoto S, Gaultier A, Hsieh EH, Lester RD, Gonias SL. Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene 2007;26(18):2585-2594.
75. Zyzak LL, MacDonald LM, Batova A, Forand R, Creek KE, Pirisi L. Increased levels and constitutive tyrosine phosphorylation of the epidermal growth factor receptor contribute to autonomous growth of human papillomavirus type 16 immortalized human keratinocytes. Cell Growth Differ 1994;5(5):537-547.
76. Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P. Integrins induce activation of EGF receptor: Role in MAP kinase induction and adhesion-dependent cell survival. EMBO J 1998;17(22):6622-6632.
77. Milanese G, Dellabella M, Fazioli F, Pierpaoli E, Polito M, Siednius N, Montironi R, Blasi F, Muzzonigro G. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer. J Urol 2009;181(3):1393-1400.
78. Jo M, Thomas KS, O'Donnell DM, Gonias SL. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem 2003;278(3):1642-1646.
79. Jo M, Thomas KS, Marozkina N, Amin TJ, Silva CM, Parsons SJ, Gonias SL. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem 2005;280(17):17449-17457.
80. D'Alessio S, Gerasi L, Blasi F. uPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro. J Cell Sci 2008;121(Pt 23):3922-3932.
81. Horowitz JC, Rogers DS, Simon RH, Sisson TH, Thannickal VJ. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol 2008;38(1):78-87.
82. Soeda S, Oda M, Ochiai T, Shimeno H. Deficient release of plasminogen activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells. Brain Res Mol Brain Res 2001;91(1-2):96-103.
83. Chen Y, Kelm RJ, Jr., Budd RC, Sobel BE, Schneider DJ. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 2004;92(1):178-188.
84. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 2007;31(1):19-27.
85. Prager GW, Mihaly J, Brunner PM, Koshelnick Y, Hoyer-Hansen G, Binder BR. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood 2009;113(6):1383-1390.
86. Schmitt M, Wilhelm O, Janicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metastasis. J Obstet Gynaecol 1995;21(2):151-165.
87. Herz J, Clouthier DE, Hammer RE. Ldl receptor-related protein internalizes and degrades Upa-Pai-1 complexes and is essential for embryo implantation. Cell 1992;71(3):411-421.
88. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004;279(21):22595-22604.
89. Prager GW, Breuss JM, Steurer S, Olcaydu D, Mihaly J, Brunner PM, Stockinger H, Binder BR. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res 2004;94(12):1562-1570.
90. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997;16(10):2610-2620.
91. Cortese K, Sahores M, Madsen CD, Tacchetti C, Blasi F. Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR. PLoS One 2008;3(11):e3730.
92. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277(5323):225-228.
93. Hangai M, Kitaya N, Xu JS, Chan CK, Kim JJ, Werb Z, Ryan SJ, Brooks PC. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 2002;161(4):1429-1143.
94. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001;154(5):1069-1079.
95. Netzel-Arnett S, Mitola DJ, Yamada SS, Chrysovergis K, Holmbeck K, Birkedal-Hansen H, Bugge TH. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem 2002;277(47):45154-45161.
96. Seiffert D, Smith JW. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 1997;272(21):13705-13710.
97. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998;91(7):2305-2312.
98. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system. Int J Cancer 1997;71(1):116-122.
99. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100(1):58-67.
100. Kjoller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 2001;152(6):1145-1157.
101. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999;144(6):1285-1294.
102. Tang CH, Hill ML, Brumwell AN, Chapman HA, Wei Y. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins. J Cell Sci 2008;121(Pt 22):3747-3756.
103. van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout JW, Verheijen J, Quax P, Karperien M, Papapoulos S, Lowik C. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001;159(3):971-982.
104. Wang XQ, Sun P, Paller AS. Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/alphabeta integrin/epidermal growth factor receptor interactions. J Invest Dermatol 2005;124(4):839-848.
105. Yebra M, Parry GC, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem 1996;271(46):29393-29399.
106. Palmieri D, Lee JW, Juliano RL, Church FC. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem 2002;277(43):40950-40957.
107. Wang J, Guo F, Wei H, Dong J, Wu J. Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma. Br J Oral Maxillofac Surg 2006;44(6):515-519.
108. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994;269(21):15223-15228.
109. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005;65(23):10794-10800.
110. Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer 2011;11:358.
111. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996;49(1-3):117-137.
112. Cierniewski CS, Malinowski M, Bednarek R, Cierniewska-Cieslak A. Adhesive and proteolytic phenotype of migrating endothelial cells induced by thymosin beta-4. Ann N Y Acad Sci 2007;1112:123-139.
113. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91(10):3527-3561.
114. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001;276(36):33964-33968.
115. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4(8):923-928.
116. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004;23(41):6986-6990.
117. Alexander RA, Prager GW, Mihaly-Bison J, Uhrin P, Sunzenauer S, Binder BR, Schutz GJ, Freissmuth M, Breuss JM. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res 2012;94(1):125-135.
118. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2(10):737-744.
119. Dvorak HF, Van DeWater L, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, Bach R, Davis GL, DeWolf W, Carvalho AC. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983;43(9):4434-4442.
120. Brown LF, Asch B, Harvey VS, Buchinski B, Dvorak HF. Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinomas. Cancer Res 1988;48(7):1920-1925.
121. Bifulco K, Longanesi-Cattani I, Gala M, G DIC, Masucci MT, Pavone V, Lista L, Arra C, Stoppelli MP, Carriero MV. The soluble form of urokinase receptor promotes angiogenesis through its Ser(8)(8)-Arg-Ser-Arg-Tyr(9)(2) chemotactic sequence. J Thromb Haemost 2010;8(12):2789-2799.
122. Poettler M, Unseld M, Mihaly-Bison J, Uhrin P, Koban F, Binder BR, Zielinski CC, Prager GW. The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration. Thromb Haemost 2012;108(2):357-366.
123. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
124. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988;62(3):531-533.
125. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salvatore M. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels. Cancer Res 1993;53(13):3198-3206.
126. Pierga JY, Bonneton C, Magdelenat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP, de Cremoux P. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 2005;114(2):291-298.
127. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60(3):636-643.
128. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94(2):116-128.
129. Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, Jakic-Razumovic J, Kovac Z, Vrbanec D. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma-A 7.5-year follow-up study. Tumori 2011;97(4):532-539.
130. Malinowsky K, Wolff C, Berg D, Schuster T, Walch A, Bronger H, Mannsperger H, Schmidt C, Korf U, Hofler H, Becker KF. uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases. Transl Oncol 2012;5(2):98-104.
131. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-5312.
132. Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol 2012;41(1):179-188.
133. Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Janicke F, Blasi F. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993;92(5):2160-2167.
134. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58(9):1843-1849.
135. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14(18):5785-5793.
136. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brunner N, Blasi F. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999;79(6):717-722.
137. Sier CF, Nicoletti I, Santovito ML, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, Sidenius N. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost 2004;91(2):403-411.
138. Ljuca D, Fatusic Z, Iljazovic E, Ahmetovic B. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn J Basic Med Sci 2007;7(2):111-116.
139. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Janicke F, Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994;55(3 Pt 1):401-409.
140. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Janicke F, Hofler H, Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 1995;55(18):3958-3963.
141. van der Burg ME, Henzen-Logmans SC, Berns EM, van Putten WL, Klijn JG, Foekens JA. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 1996;69(6):475-479.
142. Chen H, Hao J, Wang L, Li Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 2009;101(3):432-440.
143. Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O'Brien PM, Li Y. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol 2009;114(2):265-272.
144. Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol 2011;22(4):877-883.
145. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Janicke F, Schmitt M, Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999;79(11-12):1746-1751.
146. Hoffmann G, Pollow K, Weikel W, Strittmatter HJ, Bach J, Schaffrath M, Knapstein P, Melchert F, Pollow B. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin Chem Lab Med 1999;37(1):47-54.
147. Foca C, Moses EK, Quinn MA, Rice GE. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Gynecol Oncol 2000;79(2):244-250.
148. Koelbl H, Kirchheimer JC, Tatra G, Christ G, Binder BR. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Obstet Gynecol 1988;72(2):252-256.
149. Memarzadeh S, Kozak KR, Chang L, Natarajan S, Shintaku P, Reddy ST, Farias-Eisner R. Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 2002;99(16):10647-10652.
150. Dariusz S, Agnieszka M, Elzbieta R, Danuta ON, Maciej Z, Piotr D, Nowicki M. A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study. Eur J Obstet Gynecol Reprod Biol 2012;163(2):193-199.
151. Nordengren J, Fredstorp Lidebring M, Bendahl PO, Brunner N, Ferno M, Hogberg T, Stephens RW, Willen R, Casslen B. High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer 2002;97(3):379-385.
152. Saito K, Nagashima M, Iwata M, Hamada H, Sumiyoshi K, Takada Y, Takada A. The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res 1990;58(4):355-366.
153. Parolini S, Rosa D, Flagiello D, Bonardi F, Rampinelli F, Bianchi UA, Molinari Tosatti MP. Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva. Int J Tissue React 1994;16(5-6):251-258.
154. Riethdorf L, Riethdorf S, Petersen S, Bauer M, Herbst H, Janicke F, Loning T. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. J Pathol 1999;189(2):245-250.
155. Larsson G, Larsson A, Astedt B. Tissue plasminogen activator and urokinase in normal, dysplastic and cancerous squamous epithelium of the uterine cervix. Thromb Haemost 1987;58(3):822-826.
156. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994;54(24):6539-6548.
157. No JH, Jo H, Kim SH, Park IA, Kang D, Lee CH, Han SS, Kim JW, Park NH, Kang SB, Song YS. Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia. Ann N Y Acad Sci 2009;1171:100-104.
158. Shimada H, Ikeuchi M, Suwa M, Michimoto T, Ono Y, Tanada S, Himeno K, Hoshino T, Takashima E. Study on the plasma plasminogen activators in patients with malignant gynecologic tumors. Nihon Sanka Fujinka Gakkai zasshi 1989;41(9):1353-1359.
159. Daneri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A, Del Toro-Arreola S, Bravo-Cuellar A, Perez-Montfort R, Orbach-Arbouys S. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur J Cancer 1998;34(4):566-569.
160. Kobayashi H, Fujishiro S, Terao T. Biochemical markers as a predictor for lymph-node involvement in patients with cervical-cancer of the uterus. Int J Oncol 1994;4(5):1053-1059.
161. Fujishiro S, Kobayashi H, Terao T. Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer. Nihon Sanka Fujinka Gakkai zasshi 1994;46(2):129-136.
162. Sugimura M, Kobayashi H, Kanayama N, Terao T. Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus. Gynecol Oncol 1992;46(3):330-336.
163. Samouelian V, Revillion F, Alloy N, Lhotellier V, Leblanc E, Peyrat JP. Measurement of mRNA of 11 biomarkers by RT-PCR to detect lymph node involvement in cervical cancer. Int J Biol Markers 2008;23(2):74-82.
164. Steuber T, Vickers A, Haese A, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007;120(7):1499-1504.
165. Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, Dano K, Hoyer-Hansen G, Lilja H. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006;52(5):838-844.
166. Kjellman A, Akre O, Gustafsson O, Hoyer-Hansen G, Lilja H, Norming U, Piironen T, Tornblom M. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening. J Intern Med 2011;269(3):299-305.
167. Almasi CE, Brasso K, Iversen P, Pappot H, Hoyer-Hansen G, Dano K, Christensen IJ. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 2011;71(8):899-907.
168. Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thuroff JW, Pfitzenmaier J. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. BJU Int 2009;104(1):29-34.
169. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008;14(12):3785-3791.
170. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, Shariat SF. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009;69(8):886-894.
171. Kumano M, Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M. Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 2009;27(2):180-186.
172. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25(4):349-355.
173. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 2009;55(5):1124-1133.
174. Yang F, Liu R, Kramer R, Xiao W, Jordan R, Lam KS. Discovery of specific ligands for oral squamous carcinoma to develop anti-cancer drug loaded precise targeting nanotherapeutics. J Calif Dental Assoc 2012;40(12):939-943.
175. Lindberg P, Larsson A, Nielsen BS. Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int J Cancer 2006;118(12):2948-2956.
176. Gershtein ES, Batsev AF, Matyakin EG, Kushlinskii NE. Urokinase and tissue plasminogen activators and their PAI-1 inhibitor in tumors of patients with oral mucosal cancer: Relationship with the main clinical morphological factors. Bull Exp Biol Med 2010;149(3):347-350.
177. Yasuda T, Sakata Y, Kitamura K, Morita M, Ishida T. Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. Head Neck 1997;19(7):611-616.
178. Wollenberg B, Jan N, Jund R, Chaubal S, Untch M. Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1. Oncol Rep 1997;4(4):853-855.
179. Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Horch HH. Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma. Mund Kiefer Gesichtschir 2004;8(3):180-190.
180. Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Horch HH. The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma. Mund Kiefer Gesichtschir 2004;8(3):173-179.
181. Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity-Clinical relevance and prognostic value. J Craniomaxillofac Surg 2005;33(3):191-196.
182. Baker EA, Leaper DJ, Hayter JP, Dickenson AJ. Plasminogen activator system in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 2007;45(8):623-627.
183. Bacchiocchi R, Rubini C, Pierpaoli E, Borghetti G, Procacci P, Nocini PF, Santarelli A, Rocchetti R, Ciavarella D, Lo Muzio L, Fazioli F. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: An immunohistochemical study. BMC Cancer 2008;8:220.
184. Lescaille G, Menashi S, Cavelier-Balloy B, Khayati F, Quemener C, Podgorniak MP, Naimi B, Calvo F, Lebbe C, Mourah S. EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: Implications in oral tumor progression. BMC Cancer 2012;12:115.
185. Geletu G, Plamadeala P, Gogalniceanu D, Zeilhofer HF, Popescu E, Moscalu M. Urokinase-type plasminogen activator (uPA) and its inhibitor-new prognostic factors in oral squamous cell carcinoma. Rev Med Chir Soc Med Nat Iasi 2004;108(1):79-84.
186. Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S, Yamamoto E. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. Oncol Rep 2011;26(6):1555-1560.
187. Wang QX, Wang TX, Sun CF, Zhang J. Expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma. Shanghai Kou Qiang Yi Xue 2006;15(1):85-87.
188. Zhang Z, Pan J, Li L, Wang Z, Xiao W, Li N. Survey of risk factors contributed to lymphatic metastasis in patients with oral tongue cancer by immunohistochemistry. J Oral Pathol Med 2011;40(2):127-134.
189. Ghadimi MR, Mahmoodi M, Mohammad K, Rasouli M, Zeraati H, Fotouhi A. Factors affecting survival of patients with oesophageal cancer: A study using inverse Gaussian frailty models. Singapore Med J 2012;53(5):336-343.
190. Torzewski M, Sarbia M, Verreet P, Dutkowski P, Heep H, Willers R, Gabbert HE. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin Cancer Res 1997;3(12 Pt 1):2263-2268.
191. Nekarda H, Schlegel P, Schmitt M, Stark M, Mueller JD, Fink U, Siewert JR. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998;4(7):1755-1763.
192. Zhao W, Wang X, Qu B, Huang X, Wang H. Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients. Chin Med J 2002;115(5):702-704.
193. Hewin DF, Savage PB, Alderson D, Vipond MN. Plasminogen activators in oesophageal carcinoma. Br J Surg 1996;83(8):1152-1155.
194. Sier CF, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJ, Lamers CB. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993;34(1):80-85.
195. Goscinski MA, Suo ZH, Nesland JM, Chen WT, Zakrzewska M, Wang J, Zhang S, Florenes VA, Giercksky KE. Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China. Oncology 2008;75(1-2):49-59.
196. Rohrberg KS, Skov BG, Lassen U, Christensen IJ, Hoyer-Hansen G, Buysschaert I, Pappot H. Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer. Cancer Biomark 2010;7(3):141-151.
197. Tang WH, Friess H, Kekis PB, Martignoni ME, Fukuda A, Roggo A, Zimmerman A, Buchler MW. Serine proteinase activation in esophageal cancer. Anticancer Res 2001;21(4A):2249-2258.
198. Nomiya T, Nemoto K, Miyachi H, Fujimoto K, Takahashi C, Takeda K, Matushita H, Ogawa Y, Takai Y, Yamada S. Significance of plasminogen-activation system in the formation of macroscopic types and invasion in esophageal carcinoma. Anticancer Res 2002;22(5):2913-2916.
199. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000;156(2):567-575.
200. Wu F, Qu B, Wang XF, Yang CM, Wang HL. Clinical study of hemostatic molecular markers expression in patients with cancer. Zhonghua Nei Ke Za Zhi 2004;43(11):837-840.
201. Herszenyi L, Istvan G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 2008;17(5):438-445.
202. Vidal O, Metges JP, Elizalde I, Valentini M, Volant A, Molina R, Castells A, Pera M. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 2009;96(12):1443-1451.
203. Scicolone G, Sanchez V, Vauthay L, Fuentes F, Scicolone A, Scicolone L, Rapacioli M, Flores V. Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression. J Cancer Res Clin Oncol 2006;132(5):309-319.
204. Ji F, Chen YL, Jin EY, Wang WL, Yang ZL, Li YM. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 2005;11(21):3222-3226.
205. Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res 2003;9(6):2267-2276.
206. Plebani M, Herszenyi L, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F. Urokinase-type plasminogen activator receptor in gastric cancer: Tissue expression and prognostic role. Clin Exp Metastasis 1997;15(4):418-425.
207. Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H. Urokinase system expression in gastric carcinoma: Prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 2006;106(5):1026-1035.
208. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003;94(1):43-49.
209. Gerstein ES, Shcherbakov AM, Kaz'min AI, Ognerubov NA, Kushlinskii NE. Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer. Vopr Onkol 2003;49(2):165-169.
210. Zhang L, Zhao ZS, Ru GQ, Ma J. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol 2006;12(25):3970-3976.
211. Lee KH, Bae SH, Lee JL, Hyun MS, Kim SH, Song SK, Kim HS. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology 2004;66(3):210-217.
212. Zhao ZS, Wang YY, Ye ZY, Tao HQ. Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res 2009;15(4):589-596.
213. Heiss MM, Simon EH, Beyer BC, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, Allgayer H. Minimal residual disease in gastric cancer: Evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002;20(8):2005-2016.
214. Kita Y, Fukagawa T, Mimori K, Kosaka Y, Ishikawa K, Aikou T, Natsugoe S, Sasako M, Mori M. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. Br J Cancer 2009;100(1):153-159.
215. Alpizar-Alpizar W, Christensen IJ, Santoni-Rugiu E, Skarstein A, Ovrebo K, Illemann M, Laerum OD. Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. Int J Cancer 2012;131(4):E329-336.
216. Laerum OD, Ovrebo K, Skarstein A, Christensen IJ, Alpizar-Alpizar W, Helgeland L, Dano K, Nielsen BS, Illemann M. Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. Int J Cancer 2012;131(3):558-569.
217. Alpizar-Alpizar W, Nielsen BS, Sierra R, Illemann M, Ramirez JA, Arias A, Duran S, Skarstein A, Ovrebo K, Lund LR, Laerum OD. Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. Int J Cancer 2010;126(2):405-415.
218. Kushlinskii NE, Delektorskaya VV, Mochal'nikova VV, Sini L, Yurchenko AA, Ryabov AB, Stilidi IS. Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology. Bull Exp Biol Med 2008;146(6):786-790.
219. Murata S, Eguchi Y, Terata N, Tani T, Kodama M. Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer. Gastric Cancer 1998;1(1):71-77.
220. Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacin A, Castells A, Pique JM, Volant A, Metges JP. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: Results of a study assessing a panel of angiogenic markers. J Gastroint Surg 2008;12(6):1005-1014.
221. Luebke T, Baldus SE, Spieker D, Grass G, Bollschweiler E, Schneider PM, Thiele J, Dienes HP, Hoelscher AH, Moenig SP. Is the urokinase-type plasminogen activator system a reliable prognostic factor in gastric cancer? Int J Biol Markers 2006;21(3):162-169.
222. Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, De Paoli M, Plebani M, Tulassay Z. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008;8:194.
223. Papadopoulou S, Scorilas A, Yotis J, Arnogianaki N, Plataniotis G, Agnanti N, Talieri M. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol 2002;23(3):170-178.
224. Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, Hwang BD, Yoon WH. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006;6:211.
225. Langenskiold M, Holmdahl L, Angenete E, Falk P, Nordgren S, Ivarsson ML. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 2009;30(4):210-220.
226. Halamkova J, Kiss I, Pavlovsky Z, Tomasek J, Jarkovsky J, Cech Z, Tucek S, Hanakova L, Moulis M, Zavrelova J, Man M, Benda P, Robek O, Kala Z, Penka M. Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients. Neoplasma 2011;58(5):377-385.
227. Sier CF, Vloedgraven HJ, Ganesh S, Griffioen G, Quax PH, Verheijen JH, Dooijewaard G, Welvaart K, van de Velde CJ, Lamers CB, Verspaget HW. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994;107(5):1449-1456.
228. Angenete E, Langenskiold M, Palmgren I, Falk P, Oresland T, Ivarsson ML. uPA and PAI-1 in rectal cancer-relationship to radiotherapy and clinical outcome. J Surg Res 2009;153(1):46-53.
229. Konno H, Abe J, Kaneko T, Baba M, Shoji A, Sunayama K, Kamiya K, Tanaka T, Suzuki S, Nakamura S, Urano T. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res 2001;92(5):516-523.
230. Baker EA, Bergin FG, Leaper DJ. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 2000;53(6):307-312.
231. Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, Zlobec I. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol 2010;41(1):70-78.
232. Yang JL, Seetoo D, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ. Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 2000;89(5):431-439.
233. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003;82(3):184-193.
234. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994;344(8919):401-402.
235. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 1999;91(10):869-874.
236. Riisbro R, Christensen IJ, Nielsen HJ, Brunner N, Nilbert M, Fernebro E. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers 2005;20(2):93-102.
237. Fernebro E, Madsen RR, Ferno M, Brunner N, Bendahl P, Christensen IJ, Johnson A, Nilbert M. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001;37(4):486-491.
238. Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol 2000;190(2):190-195.
239. Zheng Q, Tang Z, Wu Z, Shi D, Song H. Inhibitor of plasminogen activator 1 (PAI-1) in hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 1998;36(8):474-476.
240. Zhou Q, Liang LJ, Peng BG, Zhen YY. Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients. Ai Zheng 2006;25(11):1433-1438.
241. Schoedel KE, Tyner VZ, Kim TH, Michalopoulos GK, Mars WM. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Modern Pathol 2003;16(1):14-21.
242. Zheng Q, Tang Z, Wu Z. Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis. Zhonghua Zhong Liu Za Zhi 1998;20(1):57-59.
243. Lu XG, Mao JS, Tong JF, Zhu L, Liu J, Gong XB, Huang J. Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids. Int J Lab Hematol 2007;29(2):132-138.
244. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103(4):914-921.
245. Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. Pathol Int 2000;50(5):392-397.
246. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000;126(11):641-646.
247. Akahane T, Ishii M, Ohtani H, Nagura H, Toyota T. Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. Liver 1998;18(6):414-419.
248. Meng C, Chen X. Association of VEGF, uPA, ICAM-1 and PCNA expression with metastasis and recurrence in hepato cellular carcinoma. Zhonghua Wai Ke Za Zhi 2002;40(9):673-675.
249. Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, Zhou L, Rui JA, Yamamoto M, Kuroda Y, Itoh H. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15(4):422-430.
250. Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer 2000;87(5):644-649.
251. Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, Allen BJ, Smith RC. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol 2005;20(2):256-263.
252. Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008;36(2):160-167.
253. Hildenbrand R, Niedergethmann M, Marx A, Belharazem D, Allgayer H, Schleger C, Strobel P. Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol 2009;174(6):2246-2253.
254. Chen Y, Zheng B, Robbins DH, Lewin DN, Mikhitarian K, Graham A, Rumpp L, Glenn T, Gillanders WE, Cole DJ, Lu X, Hoffman BJ, Mitas M. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer 2007;120(7):1511-1517.
255. Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G, Blasi F, Talamini G, Bassi C, Scarpa A. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 2011;11:448.
256. Shin SJ, Kim KO, Kim MK, Lee KH, Hyun MS, Kim KJ, Choi JH, Song HS. Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer. Jpn J Clin Oncol 2005;35(6):342-348.
257. Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, Venkataraman P, DeSouza N, Sait SN, Driscoll DL, Gibbs JF. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 2003;9(13):4935-4943.
258. Smith R, Xue A, Gill A, Scarlett C, Saxby A, Clarkson A, Hugh T. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg 2007;31(3):493-502; discussion 503.
259. Parolini S, Flagiello D, Cinquetti A, Gozzi R, Cristini S, Cappiello J, Nicolai P, Rusnati M, Presta M, Tosatti MM. Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer 1996;74(8):1168-1174.
260. Leto G, Tumminello FM, Gebbia N, Bazan V, Tomasino RM, Dardanoni G, Russo A. Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: Clinical implications. Int J Biol Markers 2001;16(4):245-249.
261. Wang D, Wang T. Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2005;19(12):529-531.
262. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur J Cancer 1998;34(8):1193-1197.
263. Zhao E, Han D, Yu Z, Fan E, Li Y, Zhou Z. Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2002;16(11):599-602.
264. Wang D, Wang T, Ren Z. Methylation status of uPA promoter in laryngeal squamous cell carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2006;20(9):409-411.
265. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, Chu SC. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354(1-2):91-99.
266. Chen Q, Fei J, Wu L, Jiang Z, Wu Y, Zheng Y, Lu G. Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. Oncol Lett 2011;2(4):693-699.
267. Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Pev 2011;20(4):609-618.
268. Brunner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 1999;107(1):160-167.
269. Cobos E, Jumper C, Lox C. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. Clin Appl Thromb Hemost 2003;9(3):241-246.
270. Almasi CE, Hoyer-Hansen G, Christensen IJ, Pappot H. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS 2009;117(10):755-761.
271. Almasi CE, Christensen IJ, Hoyer-Hansen G, Dano K, Pappot H, Dienemann H, Muley T. Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis. Lung Cancer 2011;74(3):510-515.
272. Jumper C, Cobos E, Lox C. The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: In vivo evidence from patients with advanced non-small cell lung cancer (NSCLC). Anticancer Res 2002;22(4):2073-2076.
273. Jiang Y, Liu Y, Shi Z, Wang B, Shang L, Xu X, Zhang S, Wang M. Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer. Zhongguo fei ai za zhi=Chinese journal of lung cancer 2011;14(1):49-53.
274. Montuori N, Mattiello A, Mancini A, Taglialatela P, Caputi M, Rossi G, Ragno P. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma. Int J Cancer 2003;105(3):353-360.
275. Delebecq TJ, Porte H, Zerimech F, Copin MC, Gouyer V, Dacquembronne E, Balduyck M, Wurtz A, Huet G. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin Cancer Res 2000;6(3):1086-1092.
276. Salden M, Splinter TA, Peters HA, Look MP, Timmermans M, van Meerbeeck JP, Foekens JA. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 2000;11(3):327-332.
277. Gershtein ES, Kushlinskii NE. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bull Exp Biol Med 2001;131(1):67-72.
278. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt M, Harbeck N. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004;24(6):4147-4161.
279. Almasi CE, Hoyer-Hansen G, Christensen IJ, Dano K, Pappot H. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 2005;48(3):349-355.
280. Pappot H, Pedersen AN, Brunner N, Christensen IJ. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: Relation to prognosis. Lung Cancer 2006;51(2):193-200.
281. Yoshino H, Endo Y, Watanabe Y, Sasaki T. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: Association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer 1998;78(6):833-839.
282. Chen WH, Wang C, Zhang YH, Yang YH, Zhan HY, Zhang LM. Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer. Zhonghua Yi Xue Za Zhi 2007;87(45):3228-3232.
283. D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE, 2nd, Kinch MS, Harpole DH, Jr. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 2001;72(4):1144-1148.
284. Liu Y, Lin D, Xiao T, Ma Y, Hu Z, Zheng H, Zheng S, Li M, Li L, Cao Y, Guo S, Han N, Di X, Zhang K, Cheng S, Gao Y. An immunohistochemical analysis-based decision tree model for estimating the risk of lymphatic metastasis in pN0 squamous cell carcinomas of the lung. Histopathology 2011;59(5):882-891.
285. Volm M, Mattern J, Koomagi R. Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival. Oncol Rep 1999;6(3):611-615.
286. Almasi CE, Drivsholm L, Pappot H, Hoyer-Hansen G, Christensen IJ. The liberated domain I of urokinase plasminogen activator receptor - a new tumour marker in small cell lung cancer. APMIS 2012.
287. Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis. Lung Cancer 2007;56(1):43-50.
288. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 2009;125(4):894-901.
289. Ito Y, Takeda T, Kobayashi T, Wakasugi E, Tamaki Y, Umeshita K, Monden T, Shimano T, Monden M. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study. Anticancer Res 1996;16(1):81-89.
290. Kushlinskii NE, Gershtein ES, Kazantseva IA, Kharitidi T, Liakina LT, Kazakov SP, Bagatyrev OP, Kalinin AP. Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases. Vestn Ross Akad Med Nauk 2001(5):32-34.
291. Chu QD, Hurd TC, Harvey S, Martinick M, Markus G, Tan D, Gibbs JF, Loree T. Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis. Diagnostic Mol Pathol 2004;13(4):241-246.
292. Kim SJ, Shiba E, Taguchi T, Tsukamoto F, Miyoshi Y, Tanji Y, Takai S, Noguchi S. uPA receptor expression in benign and malignant thyroid tumors. Anticancer Res 2002;22(1A):387-393.
293. Zanetti A, Stoppacciaro A, Marzullo A, Ciabatta M, Fazioli F, Prat M, Comoglio PM, Baroni CD, Ruco LP. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J Pathol 1998;186(3):287-291.
294. Ulisse S, Baldini E, Sorrenti S, Barollo S, Gnessi L, Catania A, Pellizzo MR, Nardi F, Mian C, De Antoni E, D'Armiento M, Frati L. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab 2011;96(2):504-508.
295. Nowicki TS, Kummer NT, Iacob C, Suslina N, Schaefer S, Schantz S, Shin E, Moscatello AL, Tiwari RK, Geliebter J. Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope 2010;120(7):1383-1390.
296. Ulisse S, Baldini E, Toller M, Marchioni E, Giacomelli L, De Antoni E, Ferretti E, Marzullo A, Graziano FM, Trimboli P, Biordi L, Curcio F, Gulino A, Ambesi-Impiombato FS, D'Armiento M. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur J Cancer 2006;42(15):2631-2638.
297. Horvatic Herceg G, Herceg D, Kralik M, Bence-Zigman Z, Tomic-Brzac H, Kulic A. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: A cytosol study. Wien Klin Wochenschr 2006;118(19-20):601-609.
298. Dormoy V, Jacqmin D, Lang H, Massfelder T. From development to cancer: Lessons from the kidney to uncover new therapeutic targets. Anticancer Res 2012;32(9):3609-3617.
299. Bashar H, Urano T, Fukuta K, Pietraszek MH, Hata M, Suzuki K, Kawabe K, Takada Y, Takada A. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int 1994;52(1):4-8.
300. Hata M. The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator. Nihon Hinyokika Gakkai zasshi The japanese journal of urology 1989;80(11):1558-1565.
301. Swiercz R, Wolfe JD, Zaher A, Jankun J. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 1998;4(4):869-877.
302. Bhuvarahamurthy V, Schroeder J, Kristiansen G, Roigas J, Denkert C, Johannsen M, Lein M, Loening SA, Schnorr D, Jung K, Staack A. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma. Oncol Rep 2005;14(3):777-782.
303. Span PN, Witjes JA, Grebenchtchikov N, Geurts-Moespot A, Moonen PM, Aalders TW, Vriesema JL, Kiemeney LA, Schalken JA, Sweep FC. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: Comparison between normal and matched cancerous tissues. BJU Int 2008;102(2):177-182.
304. Wagner SN, Atkinson MJ, Thanner S, Wagner C, Schmitt M, Wilhelm O, Rotter M, Hofler H. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol 1995;147(1):183-192.
305. Chautard D, Dalifard I, Chassevent A, Guyetant S, Daver A, Vielle B, Soret JY. Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. Urology 2004;63(6):1055-1060.
306. Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis. J Urol 2005;174(2):461-465.
307. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78(3):487-492.
308. Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 1996;155(3):858-862.
309. Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA. Four tumour markers for urinary bladder cancer-tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res 2005;25(1B):635-641.
310. Casella R, Shariat SF, Monoski MA, Lerner SP. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer 2002;95(12):2494-2499.
311. Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 2003;61(5):1053-1058.
312. Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol 2003;170(6 Pt 1):2244-2247.
313. Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, Jung K, Staack A. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. Oncol Rep 2004;12(4):909-913.
314. Li YJ, Zheng BZ, Zhou ZL. The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban 2004;35(1):57-59.
315. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 1994;151(1):16-19; discussion 19-20.
316. Hasui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996;47(1):34-37.
317. Vivani C, Magi S, Mazzucchelli R, Bacchiocchi R, Santinelli A, Muzzonigro G, Blasi F, Montironi R, Fazioli F. Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia. Anal Quant Cytol Histol 2004;26(1):15-21.
318. Seddighzadeh M, Steineck G, Larsson P, Wijkstrom H, Norming U, Onelov E, Linder S. Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms. Int J Cancer 2002;99(5):721-726.
319. Li YJ, Zheng BZ, Zhou ZL. Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma. Ai Zheng 2004;23(6):704-706.
320. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992;50(6):871-873.
321. Seddighzadeh M, Steineck G, Jansson O, Larsson P, Wijkstrom H, Adolfsson J, Portwood N, Hansson J, Linder S. Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma. Br J Cancer 2001;84(3):329-334.
322. Hasui Y, Nishi S, Kitada S, Osada Y. Urokinase-type plasminogen activator antigen as a prognostic factor in bladder cancer. Nihon Hinyokika Gakkai zasshi The japanese journal of urology 1993;84(9):1624-1628.
323. Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 1998;82(4):724-732.
324. Champelovier P, Boucard N, Levacher G, Simon A, Seigneurin D, Praloran V. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: Diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol Res 2002;30(5):301-309.
325. El-Kott AF, Khalil AM, El-Kenawy Ael M. Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma. Int Urol Nephrol 2004;36(3):417-423.
326. Iwami K, Natsume A, Wakabayashi T. Cytokine networks in glioma. Neurosurg Rev 2011;34(3):253-263; discussion 263-254.
327. Kros JM. Grading of gliomas: The road from eminence to evidence. J Neuropathol Exp Neurol 2011;70(2):101-109.
328. Perry J, Okamoto M, Guiou M, Shirai K, Errett A, Chakravarti A. Novel therapies in glioblastoma. Neurol Res Int 2012;2012:428565.
329. Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS. Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 1994;22(2):101-110.
330. Sawaya R, Yamamoto M, Ramo OJ, Shi ML, Rayford A, Rao JS. Plasminogen activator inhibitor-1 in brain tumors: Relation to malignancy and necrosis. Neurosurgery 1995;36(2):375-380; discussion 380-371.
331. Arai Y, Kubota T, Nakagawa T, Kabuto M, Sato K, Kobayashi H. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochir 1998;140(4):377-385; discussion 385-376.
332. Kandenwein JA, Park-Simon TW, Schramm J, Simon M. uPA/PAI-1 expression and uPA promoter methylation in meningiomas. J Neurooncol 2011;103(3):533-539.
333. Siddique K, Yanamandra N, Gujrati M, Dinh D, Rao JS, Olivero W. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. Int J Oncol 2003;22(2):289-294.
334. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Pfister K, Schmetzer H. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis. Am J Hematol 2005;79(1):26-35.
335. Rosc D, Kremplewska-Nalezyta E, Gadomska G, Bielis L. Hemostatic disturbances in chronic myeloid leukemia. Wiad Lek 2007;60(3-4):138-142.
336. Lanza F, Castoldi GL, Castagnari B, Todd RF, 3rd, Moretti S, Spisani S, Latorraca A, Focarile E, Roberti MG, Traniello S. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol 1998;103(1):110-123.
337. Scherrer A, Wohlwend A, Kruithof EK, Vassalli JD, Sappino AP. Plasminogen activation in human acute leukaemias. Br J Haematol 1999;105(4):920-927.
338. Liu YH, Wang ZY, Zhang W, Dai L, Shen WH, Ruan CG. Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia. Zhonghua xue ye xue za zhi=Zhonghua xueyexue zazhi 2009;30(3):145-149.
339. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: Relationship to classification and response to therapy. Thromb Haemost 1999;81(5):705-710.
340. De Vries TJ, Mooy CM, Van Balken MR, Luyten GP, Quax PH, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GN. Components of the plasminogen activation system in uveal melanoma-a clinico-pathological study. J Pathol 1995;175(1):59-67.
341. Gershtein ES, Medvedeva SV, Babkina IV, Kushlinskii NE, Trapeznikov NN. Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. Bull Exp Biol Med 2001;132(1):670-674.
342. Ferrier CM, Suciu S, van Geloof WL, Straatman H, Eggermont AM, Koops HS, Kroon BB, Lejeune FJ, Kleeberg UR, van Muijen GN, Ruiter DJ. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 2000;83(10):1351-1359.
343. Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncol Rep 2003;10(3):635-639.
344. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22(2-3):205-222.
345. Ghamande SA, Silverman MH, Huh W, Behbakht K, Ball G, Cuasay L, Wurtz SO, Brunner N, Gold MA. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol 2008;111(1):89-94.
346. Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN, Cuasay LC, Brunner N, Jones TR, Silverman MH, Gold MA. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. Gynecol Oncol 2005;99(1):50-57.
347. Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012;125(3):635-639.
348. 2005_EraofHope_WX_UK1_Poster.pdf. http://www.wilex.de/pdf/Poster/Poster_MESUPRON/2005_EraofHope_WX_UK1_Poster.pdf.
349. 2008_EraofHope_WX_MESUPRON_Poster.pdf. http://www.wilex.de/pdf/Poster/Poster_MESUPRON/2008_EraofHope_WX_MESUPRON_Poster.pdf.
350. Phase I with WX-UK1. http://www.wilex.de/portfolio-english/mesupron/phase-i-with-wx-uk1/.
351. Phase I & II with MESUPRON®. http://www.wilex.de/portfolio-english/mesupron/phase-i-ii-with-mesu/.
352. 2010_ASCO_Breast_PhII.pdf. http://www.wilex.de/pdf/Poster/Poster_MESUPRON/2010_ASCO_Breast_PhII.pdf.
353. Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer 2013;108(4):766-770.